Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7377 - 7384 of 12089 results
St. Jude Cybersecurity Vulnerability Extended to Provider-Owned Devices
February 9, 2017| Blog| Viewpoint
Securities and Exchange Commission Considers Changes to CEO Pay Ratio Rule
February 8, 2017| Blog| Viewpoint
New Rules in the Northern District of California Aim to Encourage Patent Case Settlements
February 8, 2017| Blog| Viewpoint
Firm Partners with ACLU of MA in Lawsuit Against the President’s Travel Ban
February 7, 2017| News
IMMIGRATION UPDATE: Provisional Revocation of Visas Stemming from Executive Order Lifted; Further Updates Forthcoming
February 6, 2017| Alert| Viewpoint
Are You Managing Your Cybersecurity Risks?
February 6, 2017| Blog| Viewpoint
Some of nation's largest companies file legal brief opposing Trump's travel ban
February 6, 2017| News
Nearly 100 Companies File Legal Brief Opposing Trump's Travel Ban
February 6, 2017| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|